Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Baxter
Moodys
AstraZeneca
Harvard Business School

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR DYNACIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Dynacin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00473083 ↗ Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer Completed Hoffmann-La Roche Phase 2 2009-01-01 The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
NCT00473083 ↗ Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer Completed British Columbia Cancer Agency Phase 2 2009-01-01 The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
NCT01048983 ↗ Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) Withdrawn National Cancer Institute (NCI) Phase 1/Phase 2 1969-12-31 The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
NCT01048983 ↗ Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) Withdrawn M.D. Anderson Cancer Center Phase 1/Phase 2 1969-12-31 The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
NCT01173692 ↗ Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. Completed National Cancer Institute (NCI) Phase 2 2010-07-22 The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.
NCT01173692 ↗ Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. Completed M.D. Anderson Cancer Center Phase 2 2010-07-22 The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.
NCT01219673 ↗ Symptom Burden in Head and Neck Cancer Terminated National Cancer Institute (NCI) Phase 1/Phase 2 2013-03-01 The goal of this clinical research study is to compare armodafinil, bupropion, and minocycline when given alone or in combination. Researchers want to learn about the safety and level of effectiveness of these drugs in controlling symptoms, such as the side effects of chemoradiation, when given to patients with head and neck cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dynacin

Condition Name

Condition Name for Dynacin
Intervention Trials
Head And Neck Cancer 2
Lung Cancer 2
Myeloma 2
Peripheral Neuropathy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dynacin
Intervention Trials
Lung Neoplasms 4
Carcinoma, Non-Small-Cell Lung 3
Breast Neoplasms 2
Neoplasms, Plasma Cell 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dynacin

Trials by Country

Trials by Country for Dynacin
Location Trials
United States 32
Canada 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dynacin
Location Trials
Texas 11
North Carolina 2
Michigan 2
Ohio 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dynacin

Clinical Trial Phase

Clinical Trial Phase for Dynacin
Clinical Trial Phase Trials
Phase 2 13
Phase 1/Phase 2 2
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dynacin
Clinical Trial Phase Trials
Completed 9
Active, not recruiting 3
Recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dynacin

Sponsor Name

Sponsor Name for Dynacin
Sponsor Trials
National Cancer Institute (NCI) 11
M.D. Anderson Cancer Center 11
Indiana University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dynacin
Sponsor Trials
Other 25
NIH 12
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Medtronic
AstraZeneca
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.